Home
Bjørn Tore Gjertsen's picture
Photo:
CCBIO/Ingvild Festervoll Melien

Bjørn Tore Gjertsen

Professor
  • E-mailBjorn.Gjertsen@uib.no
  • Phone+47 55 97 29 68+47 415 66 248
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen
Selected publications
  • Reikvam, Håkon; Hovland, Randi; Forthun, Rakel Brendsdal; Erdal, Sigrid; Gjertsen, Bjørn Tore; Fredly, Hanne Kristin; Bruserud, Øystein. 2017. Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells. BMC Cancer. 17:630: 1-13. doi: 10.1186/s12885-017-3620-y
  • Karjalainen, Riikka; Pemovska, Tea; Popa, Mihaela Lucia; Liu, Minxia; Javarappa, Komal K.; Majumder, Muntasir Mamun; Yadav, Bhagwan; Tamborero, David; Tang, Jing; Bychkov, Dmitrii; Kontro, Mika; Parsons, Alun; Suvela, Minna; Mayoral Safont, Mireia; Porkka, Kimmo; Aittokallio, Tero; Kallioniemi, Olli; McCormack, Emmet; Gjertsen, Bjørn Tore; Wennerberg, Krister; Knowles, Jonathan; Heckman, Caroline Akemi. 2017. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood. 130: 789-802. doi: 10.1182/blood-2016-02-699363
  • Gullaksen, Stein-Erik; Skavland, Jørn; Gavasso, Sonia; Tosevski, Vinko; Warzocha, Krzysztof; Dumrese, Claudia; Ferrant, Augustin; Gedde-Dahl, Thobias; Hellmann, Andrzej; Janssen, Jeroen; Labar, Boris; Lang, Alois; Majeed, Mohammed Waleed; Mihaylov, Georgi; Stentoft, Jesper; Stenke, Leif; Thaler, Josef; Thielen, Noortje; Verhoef, Gregor; Voglova, Jaroslava; Ossenkoppele, Gert; Hochhaus, Andreas; Hjorth-Hansen, Henrik; Mustjoki, Satu; Sopper, Sieghart; Giles, Francis; Porkka, Kimmo; Wolf, Dominik; Gjertsen, Bjørn Tore. 2017. Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica. 102: 1361-1367. doi: 10.3324/haematol.2017.167080
  • Rajala, Hanna L.M.; El Missiry, Mohamed; Ruusila, Anniina; Koskenvesa, Perttu; Brümmendorf, Tim H.; Gjertsen, Bjørn Tore; Janssen, Jeroen; Lotfi, Kourosh; Markevärn, Berit; Olsson-Strömberg, Ulla; Stenke, Leif; Stentoft, Jesper; Richter, Johan; Hjorth-Hansen, Henrik; Kreutzman, Anna; Mustjoki, Satu. 2017. Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology. 143: 1543-1554. doi: 10.1007/s00432-017-2378-6
  • Omsland, Maria; Bruserud, Øystein; Gjertsen, Bjørn Tore; Andresen, Vibeke. 2017. Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-KB inhibition in acute myeloid leukemia (AML). OncoTarget. 8: 7946-7963. doi: 10.18632/oncotarget.13853
  • Sopper, Sieghart; Mustjoki, Satu; White, Deborah; Hughes, Timothy; Valent, Peter; Burchert, Andreas; Gjertsen, Bjørn Tore; Gastl, Günther; Baldauf, Matthias; Trajanoski, Zlatko; Giles, Frank; Hochhaus, Andreas; Ernst, Thomas; Schenk, Thomas; Janssen, Jeroen J.W.M.; Ossenkoppele, Gert J.; Porkka, Kimmo; Wolf, Dominik. 2017. Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. Journal of Clinical Oncology. 35: 175-184. doi: 10.1200/JCO.2016.67.0893
  • Kotopoulis, Spiros; Stigen, Endre; Popa, Mihaela Lucia; Mayoral Safont, Mireia; Healey, Andrew; Kvåle, Svein; Sontum, Per; Gjertsen, Bjørn Tore; Gilja, Odd Helge; McCormack, Emmet. 2017. Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma. Journal of Controlled Release. 245: 70-80. doi: 10.1016/j.jconrel.2016.11.019
  • Kontro, Mika; Kumar, Anil; Majumder, Muntasir Mamun; Eldfors, Samuli; Parsons, Alun; Pemovska, Tea; Saarela, Janna; Yadav, Bhagwan; Malani, Disha; Fløisand, Yngvar; Höglund, Martin; Remes, Kari Juhani; Gjertsen, Bjørn Tore; Kallioniemi, Olli; Wennerberg, Krister; Heckman, Caroline Akemi; Porkka, Kimmo. 2017. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. Leukemia. 31: 301-309. doi: 10.1038/leu.2016.222
  • Andresen, Vibeke; Erikstein, Bjarte Skoe; Mukherjee, Herschel; Sulen, Andre; Popa, Mihaela Lucia; Sørnes, Steinar; Reikvam, Håkon; Chan, Kok-Ping; Hovland, Randi; McCormack, Emmet; Bruserud, Øystein; Myers, Andrew G.; Gjertsen, Bjørn Tore. 2016. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death & Disease. 7:e2497: 1-14. doi: 10.1038/cddis.2016.392
  • Thielen, Noortje; Richter, Johan; Baldauf, Matthias; Barbany, Gisela; Fioretos, Thoas; Giles, Francis; Gjertsen, Bjørn Tore; Hochhaus, Andreas; Schuurhuis, Gerrit Jan; Sopper, Sieghart; Stenke, Leif; Thunberg, Sarah; Wolf, Dominik; Ossenkoppele, Gert; Porkka, Kimmo; Janssen, Jeroen; Mustjoki, Satu. 2016. Leukemic stem cell quantification in newly diagnosed patients with chronic myeloid leukemia predicts response to nilotinib therapy. Clinical Cancer Research. 22: 4030-4038. doi: 10.1158/1078-0432.CCR-15-2791
  • Sulen, Andre; Gjertsen, Bjørn Tore. 2016. Leukocyte p38 and p53 proteins after environmental exposure; variation, associations and applicability. Universitetet i Bergen.
  • Helland, Øystein; Popa, Mihaela Lucia; Bischof, Katharina; Gjertsen, Bjørn Tore; McCormack, Emmet; Bjørge, Line. 2016. The HDACi panobinostat shows growth inhibition both in vitro and in a bioluminescent orthotopic surgical xenograft model of ovarian cancer. PLOS ONE. 11:e0158208. doi: 10.1371/journal.pone.0158208
  • Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Bjånes, Tormod Karlsen; Hoem, Dag; Schjøtt, Jan; Gjertsen, Bjørn Tore; Biermann, Martin; Molven, Anders; Sorbye, Halfdan; McCormack, Emmet; Postema, Michiel; Gilja, Odd Helge. 2016. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. Journal of Controlled Release. 243: 172-181. doi: 10.1016/j.jconrel.2016.10.007
  • Sulen, Andre; Gullaksen, Stein-Erik; Bader, Lucius; McClymont, David; Skavland, Jørn; Gavasso, Sonia; Gjertsen, Bjørn Tore. 2016. Signaling effects of sodium hydrosulfide in healthy donor peripheral blood mononuclear cells. Pharmacological Research. 113: 216-227. doi: 10.1016/j.phrs.2016.08.018
  • Hjorth-Hansen, Henrik; Stentoft, Jesper; Richter, Johan; Koskenvesa, Perttu; Höglund, Martin; Dreimane, Arta; Porkka, Kimmo; Gedde-Dahl, Thobias; Gjertsen, Bjørn Tore; Gruber, Franz; Stenke, Leif; Myhr-Eriksson, Kristina; Markevärn, Berit; Lübking, Anna; Vestergaard, Hanne; Udby, Lene; Bjerrum, Ole Weis; Persson, Inger; Mustjoki, Satu; Olsson-Strömberg, Ulla. 2016. Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia. 30: 1853-1860. doi: 10.1038/leu.2016.121
  • Sulen, Andre; Lygre, Stein Håkon Låstad; Hjelle, Sigrun Margrethe; Hollund, Bjørg Eli; Gjertsen, Bjørn Tore. 2016. Elevated monocyte phosphorylated p38 in nearby employees after a chemical explosion. Scientific Reports. 6:29060. doi: 10.1038/srep29060
  • Leitch, Calum; Osdal, Tereza; Andresen, Vibeke; Molland, Maren Kristine Butler; Kristiansen, Silje Elisabeth; Nguyen, Nhi Xuan; Bruserud, Øystein; Gjertsen, Bjørn Tore; McCormack, Emmet. 2016. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia. OncoTarget. 7: 8105-8118. doi: 10.18632/oncotarget.6991
  • Dimcevski, Georg Gjorgji; Kotopoulis, Spiros; Bjånes, Tormod Karlsen; Hoem, Dag; Schjøtt, Jan; Gjertsen, Bjørn Tore; Biermann, Martin; Molven, Anders; Sorbye, Halfdan; McCormack, Emmet; Postema, Michiel; Gilja, Odd Helge. 2016. Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma. Journal of Clinical Oncology. 34:e15703.
  • Gavasso, Sonia; Gullaksen, Stein-Erik; Skavland, Jørn; Gjertsen, Bjørn Tore. 2016. Single-cell proteomics: Potential implications for cancer diagnostics. Expert Review of Molecular Diagnostics. 16: 579-589. doi: 10.1586/14737159.2016.1156531
  • Kotopoulis, Spiros; Dimcevski, Georg Gjorgji; McCormack, Emmet; Postema, Michiel; Gjertsen, Bjørn Tore; Gilja, Odd Helge. 2016. Ultrasound- and microbubble-enhanced chemotherapy for treating pancreatic cancer: a phase I clinical trial. Journal of the Acoustical Society of America. 139: 2092-2092. doi: 10.1121/1.4950209
  • Engen, Caroline Benedicte Nitter; Hajjar, Ehsan; Gjertsen, Bjørn Tore. 2016. Development of personalized molecular therapy for acute myeloid leukemia. Current Pharmaceutical Biotechnology. 17: 20-29. doi: 10.2174/1389201016666150930115024
  • Show author(s) 2021. p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy. Cells.
  • Show author(s) 2021. Temperature-dependent autoactivation associated with clinical variability of PDGFRB Asn666 substitutions. Human Molecular Genetics. 72-77.
  • Show author(s) 2021. Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis. Molecular Oncology. 2285-2299.
  • Show author(s) 2021. Phenotypic Characterization by Mass Cytometry of the Microenvironment in Ovarian Cancer and Impact of Tumor Dissociation Methods. Cancers. 1-18.
  • Show author(s) 2021. Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP: Five-year follow-up of the NordCML007 study. European Journal of Haematology. 1-7.
  • Show author(s) 2021. Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System . Cancers.
  • Show author(s) 2021. FLT3-ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation. Molecular Oncology. 2300-2317.
  • Show author(s) 2021. Colony stimulating factor 1 receptor in acute myeloid leukemia. Frontiers in Oncology. 1-12.
  • Show author(s) 2021. Cerebrospinal fluid proteome shows disrupted neuronal development in multiple sclerosis. Scientific Reports.
  • Show author(s) 2020. Ultrasound‐ and microbubble‐assisted gemcitabine delivery to pancreatic cancer cells. Pharmaceutics. 1-15.
  • Show author(s) 2020. Synthesis of N-aryl- and N-alkyl-substituted imidazolium silver complexes: Cytotoxic screening by using human cell lines modelling acute myeloid leukaemia. ChemMedChem. 1509-1514.
  • Show author(s) 2020. Single cell detection of the p53 protein by mass cytometry. Cancers. 1-15.
  • Show author(s) 2020. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica. 708-720.
  • Show author(s) 2020. Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition. Leukemia. 1-11.
  • Show author(s) 2020. Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. Haematologica. 1527-1538.
  • Show author(s) 2020. Low-Intensity Sonoporation-Induced Intracellular Signalling of Pancreatic Cancer Cells, Fibroblasts and Endothelial Cells. Pharmaceutics. 1-17.
  • Show author(s) 2020. Hit to leads with cytotoxic effect in leukemic cells: Total synthesis intermediates as a molecule treasure chest. ChemMedChem. 862-870.
  • Show author(s) 2020. Exploring the boundaries of precision haemato-oncology – The case of FLT3 length mutated acute myeloid leukaemia.
  • Show author(s) 2020. Early Response to the Plant Toxin Stenodactylin in Acute Myeloid Leukemia Cells Involves Inflammatory and Apoptotic Signaling. Frontiers in Pharmacology.
  • Show author(s) 2020. CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma. EBioMedicine. 1-13.
  • Show author(s) 2020. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. Leukemia.
  • Show author(s) 2020. A microfluidic device for differential capture of heterogeneous rare tumor cells with epithelial and mesenchymal phenotypes. Analytica Chimica Acta. 1-11.
  • Show author(s) 2020. A comparison of p53 isoform profiles and apoptosis induced by camptothecin or a herbal khat extract (Catha edulis (vahl) forssk. ex endl.) in leukemic cell lines: Exploring cellular responses in therapy development. Cancers. 1-14.
  • Show author(s) 2020. A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation. Journal of Biological Chemistry. 15 pages.
  • Show author(s) 2020. Tyrosine kinase inhibitors and interferon‐α increase tunneling nanotube (TNT) formation and cell adhesion in chronic myeloid leukemia (CML) cell lines (. The FASEB Journal. 3774-3791.
  • Show author(s) 2019. ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. Scientific Reports. 1-15.
  • Show author(s) 2019. Titrating complex mass cytometry panels. Cytometry Part A. 1-6.
  • Show author(s) 2019. Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy. Cells.
  • Show author(s) 2019. Synthesis and investigation of Ag-NHC complexes with cytotoxic properties towards cell lines modelling acute myeloid leukemia .
  • Show author(s) 2019. Rethinking Gynecological High- Grade Serous Carcinoma. Portraying the p53 isoform landscape and development of a new preclinical for optical imaging in xenograft models.
  • Show author(s) 2019. Pretreatment of glioblastoma with bortezomib potentiates natural killer cell cytotoxicity through TRAIL/DR5 mediated apoptosis and prolongs animal survival. Cancers. 1-25.
  • Show author(s) 2019. Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia. Journal of Cancer Research and Clinical Oncology. 1729-1749.
  • Show author(s) 2019. Intracellular signaling in key pathways is induced by treatment with ultrasound and microbubbles in a leukemia cell line, but not in healthy peripheral blood mononuclear cells. Pharmaceutics. 1-17.
  • Show author(s) 2019. Influence of p53 isoform expression on survival in high-grade serous ovarian cancers. Scientific Reports. 1-11.
  • Show author(s) 2019. Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. Oncoimmunology. 1-13.
  • Show author(s) 2019. GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells. Haematologica.
  • Show author(s) 2019. Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: A case report. Journal of Medical Case Reports. 1-8.
  • Show author(s) 2019. Clinical trials of repurposing medicines in acute myeloid leukemia: Limitations and possibilities in the age of precision therapy. The Cancer Journal. 153-163.
  • Show author(s) 2019. Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. British Journal of Cancer. 545-555.
  • Show author(s) 2018. Update on the randomised phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma. Annals of Oncology. viii452-viii452.
  • Show author(s) 2018. Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic and transcriptomic comparison. Expert opinion on therapeutic targets. 639-653.
  • Show author(s) 2018. Single cell signalling and immune profiles in chronic myeloid leukaemia .
  • Show author(s) 2018. Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis. Biomarker Research.
  • Show author(s) 2018. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 1768-1777.
  • Show author(s) 2018. Maternal exposure to gasoline and exhaust increases the risk of childhood leukaemia in offspring - a prospective study in the Norwegian Mother and Child Cohort Study. British Journal of Cancer. 1028-1035.
  • Show author(s) 2018. Inhibition of tunneling nanotube (TNT) formation and Human T-cell leukemia virus type 1 (HTLV-1) transmission by cytarabine. Scientific Reports. 1-17.
  • Show author(s) 2018. High expression of the p53 isoform ? is associated with reduced progression-free survival in uterine serous carcinoma. BMC Cancer. 1-10.
  • Show author(s) 2018. Gene expression response in peripheral blood cells of petroleum workers exposed to sub-ppm benzene levels. International Journal of Environmental Research and Public Health (IJERPH). 1-18.
  • Show author(s) 2018. Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation. Case reports in hematology.
  • Show author(s) 2018. Cell therapy induced regeneration of severely atrophied mandibular bone in a clinical trial. . Stem Cell Research & Therapy. 1-15.
  • Show author(s) 2017. development of novel Highly Specific FLT3 Targeted Inhibitors for Combination or Sequential Therapy of Acute Myeloid Leukemia.
  • Show author(s) 2017. combination of interferon-alpha and valproic acid in acute myeloid leukemia cells in vitro and in vivo.
  • Show author(s) 2017. a precision medicin platform for acute myeloid leukemia to help unraveling the molecular addictions of FLT3-ITD-driven AML.
  • Show author(s) 2017. Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology. 1543-1554.
  • Show author(s) 2017. Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-KB inhibition in acute myeloid leukemia (AML). OncoTarget. 7946-7963.
  • Show author(s) 2017. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. Blood. 1636-1645.
  • Show author(s) 2017. Stroma-derived factors stimulate JAK/STAT signaling in AML cells resulring in resistance to BCL2 inhibitor Venetoclax.
  • Show author(s) 2017. Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma. Journal of Controlled Release. 70-80.
  • Show author(s) 2017. Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica. 1361-1367.
  • Show author(s) 2017. Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia. Journal of Clinical Oncology. 175-184.
  • Show author(s) 2017. Proteomics and single cell immune and signaling profiling of myeloid leukemia.
  • Show author(s) 2017. Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. Journal of Proteomics. 32-41.
  • Show author(s) 2017. NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib. Leukemia. 2264-2267.
  • Show author(s) 2017. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood. 789-802.
  • Show author(s) 2017. In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL. Blood Cancer Journal. 4 pages.
  • Show author(s) 2017. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. Leukemia. 301-309.
  • Show author(s) 2017. Drug Repurposing for the Treatment of Acute Myeloid Leukemia. Frontiers in medicine.
  • Show author(s) 2017. Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells. BMC Cancer. 1-13.
  • Show author(s) 2017. Biomarker Panels and Contemporary Practice in Clinical Trials of Targeted Therapy. 19 pages.
  • Show author(s) 2016. Ultrasound- and microbubble-enhanced chemotherapy for treating pancreatic cancer: a phase I clinical trial. Journal of the Acoustical Society of America. 2092-2092.
  • Show author(s) 2016. Ultrasound- and microbubble-enhanced chemotherapy for treating pancreatic cancer: A phase I clinical trial. Journal of the Acoustical Society of America.
  • Show author(s) 2016. Ultrasound and microbubble enhanced treatment of inoperable pancreatic adeonocarcinoma. Journal of Clinical Oncology.
  • Show author(s) 2016. The HDACi panobinostat shows growth inhibition both in vitro and in a bioluminescent orthotopic surgical xenograft model of ovarian cancer. PLOS ONE.
  • Show author(s) 2016. Single-cell proteomics: Potential implications for cancer diagnostics. Expert Review of Molecular Diagnostics. 579-589.
  • Show author(s) 2016. Signaling effects of sodium hydrosulfide in healthy donor peripheral blood mononuclear cells. Pharmacological Research. 216-227.
  • Show author(s) 2016. Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients. Leukemia. 1853-1860.
  • Show author(s) 2016. Leukocyte p38 and p53 proteins after environmental exposure; variation, associations and applicability.
  • Show author(s) 2016. Leukemic stem cell quantification in newly diagnosed patients with chronic myeloid leukemia predicts response to nilotinib therapy. Clinical Cancer Research. 4030-4038.
  • Show author(s) 2016. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia. OncoTarget. 8105-8118.
  • Show author(s) 2016. Elevated monocyte phosphorylated p38 in nearby employees after a chemical explosion. Scientific Reports.
  • Show author(s) 2016. Development of personalized molecular therapy for acute myeloid leukemia. Current Pharmaceutical Biotechnology. 20-29.
  • Show author(s) 2016. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death & Disease. 1-14.
  • Show author(s) 2016. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. Journal of Controlled Release. 172-181.
  • Show author(s) 2015. Sonoporation using Acoustic Cluster Therapy in combination With chemotherapy transiently reduces tumour volume. 1 pages.
  • Show author(s) 2015. Sonoporation using Acoustic Cluster Therapy in combination With chemotherapy transiently reduces tumour volume.
  • Show author(s) 2015. Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 mediate the cellular localization of nucleophosmin and its aml-associated mutants. ACS Chemical Biology. 855-863.
  • Show author(s) 2015. Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. OncoTarget. 2794-2811.
  • Show author(s) 2015. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia. 11-19.
  • Show author(s) 2015. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: Clinical results from a randomised phase-2 study (NordCML006). European Journal of Haematology. 243-250.
  • Show author(s) 2015. Bør hver kreftpasient bli et eget forskningsprosjekt? Aftenposten (morgenutg. : trykt utg.).
  • Show author(s) 2015. Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunology and Immunotherapy. 337-347.
  • Show author(s) 2015. Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunology and Immunotherapy. 337-347.
  • Show author(s) 2015. 4-alkylated silver-N-heterocyclic carbene (NHC) complexes with cytotoxic effects in leukemia cells. ChemMedChem. 1522-1527.
  • Show author(s) 2014. Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukemic compound PEP005 in primary AML cells. Oncoscience. 529-539.
  • Show author(s) 2014. Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions. Journal of Clinical Medicine.
  • Show author(s) 2014. Sonoporation: from the lab to human clinical trials. IEEE International Ultrasonics Symposium Proceedings. 846-849.
  • Show author(s) 2014. Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft. Molecular Imaging and Biology. 53-62.
  • Show author(s) 2014. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. Cell Stem Cell. 431-446.
  • Show author(s) 2014. Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines. Proteomics. 1971-1976.
  • Show author(s) 2014. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. Leukemia. 1738-1742.
  • Show author(s) 2014. Mot en mer spesifikk kreftbehandling? :. Tidsskrift for Den norske legeforening. 1017.
  • Show author(s) 2014. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Molecular Cancer.
  • Show author(s) 2014. First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma. PLOS ONE.
  • Show author(s) 2014. Evaluation of the effects of clinical diagnostic ultrasound in combination with ultrasound contrast agents on cell stress: Single cell analysis of intracellular phospho-signaling pathways in blood cancer cells and normal blood leukocytes. IEEE International Ultrasonics Symposium Proceedings. 1186-1190.
  • Show author(s) 2014. Deficient phosphorylation of stat-1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta. PLOS ONE.
  • Show author(s) 2014. Cell-to-Cell Communication in Acute Myeloid Leukemia by Tunneling Nanotubes.
  • Show author(s) 2014. A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. Leukemia and Lymphoma. 2114-2119.
  • Show author(s) 2013. cAMP signalling inhibits p53 acetylation and apoptosis via HDAC and SIRT deacetylases. International Journal of Oncology. 1815-1821.
  • Show author(s) 2013. Ultrasound-assisted treatment of an inoperable pancreatic cancer. 4 pages.
  • Show author(s) 2013. Ultrasound combined with microbubbles modulates signal transduction pathways in blood cells. 2 pages.
  • Show author(s) 2013. Ultrasound and microbubble enhanced therapy of orthotopic human pancreatic cancer in mice. 3 pages.
  • Show author(s) 2013. Tunneling nanotube (TNT) formation is independent of p53 expression. Cell Death and Differentiation. 1124-1124.
  • Show author(s) 2013. The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clinical Epigenetics.
  • Show author(s) 2013. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions? Current Cancer Drug Targets. 30-47.
  • Show author(s) 2013. Phosphoprotein signaling in acute myeloid leukemia.
  • Show author(s) 2013. Panobinostat / carboplatin delay postsurgical relapse of ovarian carcinomas in an orthotopic mouse model.
  • Show author(s) 2013. PANOBINOSTAT / CARBOPLATIN DELAY POSTSURGICAL RELAPSE OF OVARIAN CARCINOMA IN AN ORTHOTOPIC MOUSE MODEL. International Journal of Gynecological Cancer. 1 pages.
  • Show author(s) 2013. Nitroreductase, a near-infrared reporter platform for in vivo time-domain optical imaging of metastatic cancer. Cancer Research. 1276-1286.
  • Show author(s) 2013. Målrettet behandling av akutt myelogen leukemi - hemmere mot FLT3 og andre kinaser viser vei. Best Practice.
  • Show author(s) 2013. Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. Blood. E34-E42.
  • Show author(s) 2013. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discovery. 1416-1429.
  • Show author(s) 2013. Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. Expert Opinion on Investigational Drugs. 551-563.
  • Show author(s) 2013. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia. 1520-1526.
  • Show author(s) 2013. Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clinical Epigenetics.
  • Show author(s) 2013. Histone deacetylase inhibisjon i kombinasjon med platinum i en klinisk relevant ortotopisk musemodel for ovarialcancer.
  • Show author(s) 2013. Gel2DE-A software tool for correlation analysis of 2D gel electrophoresis data. BMC Bioinformatics. 5 pages.
  • Show author(s) 2013. Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen. BMC Cancer.
  • Show author(s) 2013. Expression of TP53 isoforms p53 beta or p53 gamma enhances chemosensitivity in TP53(null) cell lines. PLOS ONE. 11 pages.
  • Show author(s) 2013. Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine. BMC Pharmacology & Toxicology. 13 pages.
  • Show author(s) 2013. Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis. Cell Death & Disease.
  • Show author(s) 2013. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1-and LAGE-1-positive tumors. Cancer Immunology and Immunotherapy. 773-785.
  • Show author(s) 2012. Volume visualization for exploration of population trends in two-dimensional gel electrophoresis protein data. Computer-Based Medical Systems. 1-6.
  • Show author(s) 2012. Targeting of polo-like kinases and their cross talk with Aurora kinases - possible therapeutic strategies in human acute myeloid leukemia? Expert Opinion on Investigational Drugs. 587-603.
  • Show author(s) 2012. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia. 910-917.
  • Show author(s) 2012. Single cell pStat1 activation, a promising biomarker to evaluate neutralizing antibody effects in interferon-beta treated multiple sclerosis patients. Journal of Neuroimmunology. 18-19.
  • Show author(s) 2012. Microbubbles and cell interactions. 2 pages.
  • Show author(s) 2012. Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation. Cell Death and Differentiation. 1381-1389.
  • Show author(s) 2012. Leukocyte p53 protein biosignature through standard-aligned two-dimensional immunoblotting. Journal of Proteomics. 69-78.
  • Show author(s) 2012. Investigation of therapy resistance mechanisms in myeloid leukemia by protein profiling of bone marrow extracellular fluid. Espert Review of Proteomics. 595-598.
  • Show author(s) 2012. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis. Multiple Sclerosis. 1116-1124.
  • Show author(s) 2012. Human cells and the Norwegian Health Research Act. Tidsskrift for Den norske legeforening. 540-542.
  • Show author(s) 2012. Flow cytometic characterization and sorting of ultrasound contrast agents. 13 pages.
  • Show author(s) 2012. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status - consequences and potentials for pharmacological intervention. British Journal of Haematology. 468-480.
  • Show author(s) 2012. Establishment of a bioluminescence orthotopic mouse model of ovarian carcinoma: Analysis of tumor growth and response to therapy. Acta Obstetricia et Gynecologica Scandinavica. 16-17.
  • Show author(s) 2012. Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines. Cell Biology and Toxicology. 201-212.
  • Show author(s) 2012. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. American Journal of Hematology. 368-376.
  • Show author(s) 2012. Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. European Journal of Clinical Investigation. 1016-1026.
  • Show author(s) 2012. Deformation of acute myeloid leukaemia cells in micro-constriction array; a novel tool to study cell stress signalling.
  • Show author(s) 2012. Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid. PLOS ONE.
  • Show author(s) 2012. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene. 1533-1545.
  • Show author(s) 2012. A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline. Blood. 2 pages.
  • Show author(s) 2011. Untangling the intracellular signalling network in cancer - a strategy for data integration in acute myeloid leukemia. Journal of Proteomics. 269-281.
  • Show author(s) 2011. Stratification of pediatric acute myeloid leukemia through cancer cell gene-expression profiling. Expert Review of Anticancer Therapy. 355-357.
  • Show author(s) 2011. Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia. Blood Cancer Journal.
  • Show author(s) 2011. Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncology Reports. 1549-1556.
  • Show author(s) 2011. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Clinical and Experimental Metastasis. 234-235.
  • Show author(s) 2010. Protein kinase A activators and the pan-PPAR agonist tetradecylthioacetic acid elicit synergistic anti-leukaemic effects in AML through CREB. Leukemia Research. 77-84.
  • Show author(s) 2010. OXYGEN LEVELS INFLUENCE THE CYTOKINE RELEASE PROFILE OF AML CELLS. Experimental Hematology. S119-S119.
  • Show author(s) 2010. Lentinan: hematopoietic, immunological, and efficacy studies in a syngeneic model of acute myeloid leukemia. Nutrition and Cancer. 574-583.
  • Show author(s) 2010. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunology.
  • Show author(s) 2010. Hypoxia increases HIF-1 alpha expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. European Cytokine Network. 154-164.
  • Show author(s) 2010. Combined epigenetic and signal transduction therapy modulate specific signal transduction patterns in acute myeloid leukemia. Haematologica. 510-510.
  • Show author(s) 2010. Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia - a report of five cases. Hematology. 338-343.
  • Show author(s) 2010. Clinical proteomics of myeloid leukemia. Genome Medicine.
  • Show author(s) 2010. Cellular stress induced by resazurin leads to autophagy and cell death via production of reactive oxygen species and mitochondrial impairment. Journal of Cellular Biochemistry. 574-584.
  • Show author(s) 2010. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proceedings of the National Academy of Sciences of the United States of America. 1124-1129.
  • Show author(s) 2010. Access to the spleen microenvironment through lymph shows local cytokine production, increased cell flux, and altered signaling of immune cells during lipopolysaccharide-induced acute inflammation. Journal of Immunology. 4547-4556.
  • Show author(s) 2009. The protein kinase C agonist PEP005 increases NF-kB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. British Journal of Haematology. 761-774.
  • Show author(s) 2009. Targeted therapy in acute myeloid leukaemia: current status and future directions. Expert Opinion on Investigational Drugs. 433-455.
  • Show author(s) 2009. TARGETING THE TUMOR STROMA: A NOVEL THERAPEUTIC STRATEGY BASED ON SEPARATE ANALYSIS OF THE MALIGNANT AND STROMAL CELL COMPARTMENTS IN BRAIN TUMORS. Neuro-Oncology. 965-965.
  • Show author(s) 2009. Signalhemmere. 24 pages.
  • Show author(s) 2009. Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. British Journal of Haematology. 53-68.
  • Show author(s) 2009. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. British Journal of Haematology. 53-68.
  • Show author(s) 2009. Nuclear Factor-kappaB Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia. Critical reviews in oncogenesis. 1-41.
  • Show author(s) 2009. Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells. Leukemia Research. 276-287.
  • Show author(s) 2009. Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumour model. Neoplasia. 812-822.
  • Show author(s) 2009. Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. BMC Cancer.
  • Show author(s) 2009. Er høyt hemoglobinnivå farlig? Tidsskrift for Den norske legeforening. 1881-1882.
  • Show author(s) 2009. Early loss of mitochondrial inner transmembrane potential in khat-induced cell death of primary normal human oral cells. Toxicology. 108-116.
  • Show author(s) 2009. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. European Journal of Pharmacology. 6-22.
  • Show author(s) 2009. Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines. Molecular Cancer.
  • Show author(s) 2009. A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leukemia Research. 779-787.
  • Show author(s) 2008. Review: genetic models of acute myeloid leukaemia. Oncogene. 3765-3779.
  • Show author(s) 2008. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia. 287-293.
  • Show author(s) 2008. Khat induces G1-phase arrest and increased expression of stress-sensitive p53 and p16 proteins in normal human oral keratinocytes and fibroblasts. European Journal of Oral Sciences. 23-30.
  • Show author(s) 2008. Interferon-beta signal transduction, multiple sclerosis and auto-antibodies. Journal of Neuroimmunology. 134-135.
  • Show author(s) 2008. In vivo biological effects of ATRA in the treatment of AML. Expert Opinion on Investigational Drugs. 1623-1633.
  • Show author(s) 2008. FLT3 internal tandem duplication involving its libiquitin dependent endocytosis motif suspend modulation by HDM2 and are associated with inferior survival in AML. Haematologica. 10-10.
  • Show author(s) 2008. Evaluation of combinational therapy of MDM2-antagonist nutlin-3 and HDAC-inhibitor valproic acid in acute myeloid leukemia in vitro and in vivo. Blood. 1024-1024.
  • Show author(s) 2008. Erythropoietin a safe bet in haemorrhagic shock? Acta Anaesthesiologica Scandinavica. 585-586.
  • Show author(s) 2008. Effects of benzene on human hematopoiesis. The Open Hematology Journal. 87-102.
  • Show author(s) 2008. Comprehensive Analysis of Gene Function: RNA interference and Chemical Genomics. 13 pages.
  • Show author(s) 2008. Anticancer Immunotherapy in Combination with Proapoptotic Therapy. Current Cancer Drug Targets. 666-675.
  • Show author(s) 2008. Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death. Blood. 2866-2877.
  • Show author(s) 2007. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. British Journal of Haematology. 814-828.
  • Show author(s) 2007. Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling. Expert opinion on therapeutic targets. 1055-1069.
  • Show author(s) 2007. T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005. Cancer Immunology and Immunotherapy. 013-925.
  • Show author(s) 2007. Synergistic anti-leukemic effect of protein kinase a activator and PPAR7agonist is independent of Bcl-2 status. Blood. 117B-117B.
  • Show author(s) 2007. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica. 332-341.
  • Show author(s) 2007. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells. Molecular Cancer.
  • Show author(s) 2007. New lessons from an "old" drug: A proteomic study of anthracycline-induced apoptosis in acute myelogenous leukemia.
  • Show author(s) 2007. Linking susceptibility to histone deactylase inhibitors and basal gene expression profiles in acute myeloid leukaemia. Experimental Hematology. 77-77.
  • Show author(s) 2007. LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro. Molecular Cancer.
  • Show author(s) 2007. In vivo optical imaging of p53 specific targeted therapy in Acute Myeloid Leukaemia.
  • Show author(s) 2007. In vivo optical Imaging of acute myeloid leukemia by green fluorescent protein: Time-domain autofluorescence decoupling, fluorophore quantification, and localization. Molecular Imaging. 193-204.
  • Show author(s) 2007. Immunological aspects of acute myelogenous leukemia.
  • Show author(s) 2007. Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cells. Current Pharmaceutical Biotechnology. 388-400.
  • Show author(s) 2007. Global gene expression in classification, pathogenetic understanding and identification of therapeutic targets in Acute Myeloid Leukemia. Current Pharmaceutical Biotechnology. 344-354.
  • Show author(s) 2007. Functional characteristics and gene expression profiles of primary acute myeloid leukamia cells indentify patient subgroups that differ susceptibility to histone deactylase inhibitors. International Journal of Oncology. 1529-1538.
  • Show author(s) 2007. Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in the susceptibility to histone deacetylase inhibitors. Haematologica. 112-112.
  • Show author(s) 2007. Flt3 receptor tyrosine kinase in AML and its modulation of the p53/Hdm2/Bcl-2 pathway.
  • Show author(s) 2007. Flt3 mutations in proximity to an ubiquitin dependent endocytosis motif suspend its Hdm2 modulation. Blood. 148B-148B.
  • Show author(s) 2007. Flt3 Y591 duplication and Bc1-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood. 2589-2596.
  • Show author(s) 2007. Flt3 Mutations in Proximity to an Ubiquitin Dependent Endocytosis Motif Suspend Its Hdm2 Modulation.
  • Show author(s) 2007. Effects of interferon gamma on native human acute myelogenous leukaemia cells. Cancer Immunology and Immunotherapy. 13-24.
  • Show author(s) 2007. Early protein and gene modulation in response to induction chemotherapy of acute myeloid leukemia.
  • Show author(s) 2007. Early gene expression signature of chemotherapy treated acute myeloid leukemia in vivo.
  • Show author(s) 2007. Early gene expression of acute myeloid leukemia in response to chemotherapy. Expert Review of Anticancer Therapy. 741-751.
  • Show author(s) 2007. Early Protein and Gene Modulation in Response to Induction Chemotherapy of Acute Myeloid Leukemia.
  • Show author(s) 2007. Discrimination and quantification of spectrally similar near-infrared probes by time-domain (TD) optical imaging in acute myeloid leukemia mouse models. Blood. 147B-148B.
  • Show author(s) 2007. Discrimination and Quantification of Spectrally Similar Near-Infrared Probes by Time-Domain (TD) Optical Imaging in AML models.
  • Show author(s) 2007. Development of a near infrared reporter system for in vivo imaging.
  • Show author(s) 2007. Development and evaluation of labeled antibodies as optical contrast reagents in acute myeloid leukemia (AML).
  • Show author(s) 2007. Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. European Journal of Haematology. 210-225.
  • Show author(s) 2007. Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization. Analytical Biochemistry. 46-58.
  • Show author(s) 2007. Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex. Hematology. 199-207.
  • Show author(s) 2007. Bcl-2 antisense in the treatment of human malignancies: A delusion in targeted therapy. Current Pharmaceutical Biotechnology. 373-381.
  • Show author(s) 2007. Anti-tumor activity of immunoproteasome selective inhibitors. Blood. 477A-478A.
  • Show author(s) 2007. Anti-Tumor Activity of Immunoproteasome Selective Inhibitors.
  • Show author(s) 2006. p53 protein biosignatures in acute myeloid leukemia.
  • Show author(s) 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. International Journal of Oncology. 1065-1080.
  • Show author(s) 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation.
  • Show author(s) 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. NBS-nytt. 106.
  • Show author(s) 2006. Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused a persistent increase in peripheral blood platelet counts for a patient with acute myelogenous leukemia. Acta Oncologica. 346-349.
  • Show author(s) 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy. International Journal of Molecular Medicine. S65.
  • Show author(s) 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy.
  • Show author(s) 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy.
  • Show author(s) 2006. Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2 : Bax ratio and low levels of heat shock protein 70 and 90. Leukemia Research. 1531-1540.
  • Show author(s) 2006. Proteomics of p53 in diagnostics and therapy of acute myeloid leukemia. Current Pharmaceutical Biotechnology. 199-207.
  • Show author(s) 2006. Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies. Current Pharmaceutical Biotechnology. 185-198.
  • Show author(s) 2006. Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML). Current Pharmaceutical Biotechnology. 159-170.
  • Show author(s) 2006. Proteomic strategies for individualizing therapy of acute myeloid leukemia (AML). Current Pharmaceutical Biotechnology. 159-170.
  • Show author(s) 2006. Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert opinion on therapeutic targets. 51-68.
  • Show author(s) 2006. Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia? Cancer Immunology and Immunotherapy. 221-228.
  • Show author(s) 2006. Immunotherapy in chronic lymphocytic leukemia. Cancer Immunology and Immunotherapy. 185-187.
  • Show author(s) 2006. Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables. BMC Bioinformatics. 198.
  • Show author(s) 2006. CaM-kinasell-dependent commitment to microcystin-induced apoptosis is coupled to cell budding, but not to shrinkage or chromatin hypercondensation. Cell Death and Differentiation. 1191-1202.
  • Show author(s) 2006. Adaptive contrast enhancement of two-dimensional electrophoretic protein gel images facilitates visualization, orientation and alignment. Electrophoresis. 4086-4095.
  • Show author(s) 2006. Acute myelogenous leukemia in a patient with Li-Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report. Leukemia. 734-736.
  • Show author(s) 2006. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clinical Cancer Research. 3985-3992.
  • Show author(s) 2005. The role of Bcl-2 in apoptosis induced by khat (Catha edulis) in acute myeloid leukemia cell lines. Blood. 195b-195b.
  • Show author(s) 2005. Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy. Current Drug Targets. 631-646.
  • Show author(s) 2005. Proteomics in acute myelogenous leukaemia (AML): Methodological strategies-and identification of protein targets for novel antileukaemic therapy. Current Drug Targets. 631-646.
  • Show author(s) 2005. Khat- and cathionine-induced apoptosis is modulated by Bcl-2 protein expression.
  • Show author(s) 2005. Antiangiogenic therapy in acute myelogenous leukemia: Targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Current Cancer Drug Targets. 229-248.

More information in national current research information system (CRIStin)

Twitter